-
Mashup Score: 0ASCO Plenary Series Program - 7 month(s) ago
Learn more about the faculty and program for the November Plenary Series session.
Source: old-prod.asco.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0Patients With Advanced Gastric, Esophageal Cancer Report Better HRQOL Outcomes With Nivolumab-Based Therapy - 7 month(s) ago
Nivolumab plus chemotherapy offered patients with gastric and esophageal cancers reduced risk of symptom burden and longer time to deterioration.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Patients With Advanced Gastric, Esophageal Cancer Report Better HRQOL Outcomes With Nivolumab-Based Therapy - 7 month(s) ago
Nivolumab plus chemotherapy offered patients with gastric and esophageal cancers reduced risk of symptom burden and longer time to deterioration.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Claudin 18.2 and FGFR2b as novel targets in gastric cancer - 7 month(s) ago
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the development of novel targeted therapies for gastric cancer. In addition to microsatellite instability (MSI) high and PD-L1, claudin 18.2 and FGFR2b have been identified as promising targets. Zolbetuximab, and anti-claudin 18.2 antibody has improved survival in patients with gastric cancer in the Phase III SPOTLIGHT trial (NCT03504397). Bemarituzumab has additionally validated FGFR2b as a target in the first-line setting. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Quality of Life With Nivolumab Plus Chemotherapy in Advanced Gastric/GEJ Cancer or Esophageal Adenocarcinoma - The ASCO Post - 7 month(s) ago
As reported in the Journal of Clinical Oncology, Markus Moehler, MD, and colleagues found that in the phase III CheckMate 649 trial, the addition of nivolumab to chemotherapy was associated with generally better patient-reported health-related quality of life outcomes in patients with advanced non–HER2-positive (HER2-negative or unknown HER2 status) gastric/gastroesophageal junction cancer or esophageal adenocarcinoma. The trial supported the April 2021 approval of nivolumab in combination with fluoropyrim
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Novel Targeted Therapy Combination May Be an Effective First-Line Option for Gastric or Gastroesophageal Junction Adenocarcinoma - The ASCO Post - 8 month(s) ago
Researchers have found that the novel targeted therapy zolbetuximab in combination with a standard chemotherapy may extend survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and overexpression of the claudin-18 isoform 2 protein (CLDN18.2), according to a novel study published by Shah et al in Nature Medicine. Gastric cancer is the fifth most diagnosed cancer type globally, and its incidence has increased significantly over the last few decades. Patients with gastric
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 9 month(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
PURPOSE Trastuzumab-containing chemotherapy is the recommended first-line regimen for human epidermal growth factor receptor 2 (HER2)–positive advanced gastric or gastroesophageal junction (G/GEJ) cancer. We evaluated the safety and efficacy of trastuzumab combined with ramucirumab and paclitaxel as second-line treatment for HER2-positive G/GEJ cancer. PATIENTS AND METHODS Patients with HER2-positive advanced G/GEJ cancer who progressed after first-line treatment with trastuzumab-containing chemotherapy were enrolled from five centers in the Republic of Korea. Patients were administered a 28-day cycle of trastuzumab (once on days 1, 8, 15, and 22: 2 mg/kg followed by 4 mg/kg loading dose), ramucirumab (once on days 1 and 15: 8 mg/kg), and paclitaxel (once on days 1, 8, and 15: dose level 1, 80 mg/m2; or dose level -1, 70 mg/m2). Phase II was conducted with the recommended phase II dose (RP2D). Primary end points were determination of RP2D during phase Ib and investigator-assessed progr
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0VJOncology – The video journal of oncology - 9 month(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
By Matthew Stenger Posted: 7/11/2023 9:23:00 AM Last Updated: 7/11/2023 11:48:07 AM In a Korean phase Ib/II trial reported in the Journal of Clinical Oncology, Kim et al found that trastuzumab combined with ramucirumab and paclitaxel showed activity in the second-line treatment of patients with HER2-positive…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
📢 Just Announced: The November 7 #ASCOPlenarySeries session will ft. new research on advanced gastroesophageal cancers from @YJanjigianMD and Dr. Rui-Hua Xu. Expert discussion and Q&A to follow. Learn more: https://t.co/5bh2BocCeH #gicsm #gastriccancer #stcsm https://t.co/vqwyRkYC4q